Hsbc Holdings PLC Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Hsbc Holdings PLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 61,582 shares of the biopharmaceutical company’s stock after acquiring an additional 4,712 shares during the quarter. Hsbc Holdings PLC’s holdings in Alnylam Pharmaceuticals were worth $14,515,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ALNY. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $61,160,000. Strategic Financial Concepts LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $41,529,000. Truist Financial Corp increased its holdings in Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after buying an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after buying an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after buying an additional 2,285 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $251.56 on Monday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a twelve month low of $143.50 and a twelve month high of $304.39. The company’s 50 day moving average is $247.37 and its 200 day moving average is $255.84. The company has a market cap of $32.72 billion, a PE ratio of -115.93 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,561 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $398,320.37. Following the sale, the chief marketing officer now owns 13,537 shares in the company, valued at approximately $3,454,236.29. This trade represents a 10.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,392 shares of company stock worth $1,875,627. Insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ALNY shares. Citigroup lifted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a report on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Needham & Company LLC reissued a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a “buy” rating and a $353.00 price objective on the stock. Finally, Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.